Please Wait...

Luitpold Pharmaceuticals Chooses BioClinica Express EDC

– Vendor Flexibility and Technology Suite Cited as Key to Selection –

August 1, 2012

August 1, 2012.  NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that Luitpold Pharmaceuticals, a pioneer in the development and marketing of a wide variety of drugs and medical devices, will use BioClinica's Express Electronic Data Capture ("EDC") system for multiple upcoming clinical trials.

Luitpold selected BioClinica's Express EDC after a comprehensive search and vendor evaluation process, citing the company's flexibility during the bidding process and advanced technology as important factors in the decision.

"The transparency of BioClinica's solutions and accessibility of the project management team will make BioClinica a true partner in the clinical trial process," said Marc L. Tokars, Vice President of Clinical Operations for Luitpold. "We're excited by the possibilities that BioClinica's advanced technology will bring to Luitpold's future clinical trials."

BioClinica's Express EDC makes every part of the clinical trial process more efficient and easier to manage. Express is a comprehensive EDC solution that uses time-tested, stable technology to provide a central hub to coordinate and organize the collection and dissemination of clean data, adding speed and quality to every part of the clinical trial process.

"We are pleased Luitpold has selected BioClinica's Express EDC for their upcoming trials," said Peter Benton, President of BioClinica's eClinical division. "Luitpold has a proud tradition of pharmaceutical innovation, and we are extremely pleased that BioClinica's comprehensive suite of eClinical solutions will help them continue to bring new drugs to market."

About Luitpold Pharmaceuticals, Inc.
Luitpold Pharmaceuticals, Inc., a Daiichi Sankyo Group Company, headquartered in Shirley, NY, manufactures over 80 pharmaceutical products including Venofer® (iron sucrose injection, USP), the # 1 selling IV iron therapy in the U.S., which are distributed through its human health subsidiary, American Regent, Inc. Luitpold Pharmaceuticals, also markets dental bone regeneration products and veterinary pharmaceuticals through its Osteohealth and Animal Health divisions respectively. Sprix® (ketorolac tromethamine) Nasal Spray is marketed through its Regency Therapeutics Division. For more information on Luitpold or any of its divisions and products, please visit: www.luitpold.com.

About Bioclinica
Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized by three business segments to deliver focused service supporting multifaceted technologies. The Medical Imaging & Biomarkers segment provides medical imaging and cardiac safety services and includes a molecular marker laboratory. The eHealth Solutions segment comprises the eClinical Solutions platform; Randomization & Trial Supply Management; Financial Lifecycle Solutions; Safety & Regulatory Solutions; Strategic Consulting Services; App xChange Alliances; and eHealth Cloud Services. Under the Global Clinical Research segment, Bioclinica offers a network of investigative sites, patient recruitment services, and a post-approval research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices and research sites in the U.S., Europe, Asia, and Latin America.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @Xtalks: Outsourcing to #CROs? Top 5 Reasons to Consider Bringing CTMS & Quality Management/RBM Systems in House @bioclinica https://t.c…
bioclinica (9 hours ago)
Webinar tom! Take a fresh look at in-house vs. outsourced #CTMS & #RBM systms via case studies & ROI… https://t.co/cXKG3UgaGp
bioclinica (14 hours ago)
Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned. Join us at 11 AM EDT today in a live webinar.… https://t.co/1jiraT9cSL
bioclinica (Yesterday)
Still time to join us for tomorrow's webinar: Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned https://t.co/Ho13oUxdly
bioclinica (2 days ago)
ICYMI: Clean Patient Optics: helping #ClinicalResearch teams meet or beat database lock. News https://t.co/adWwISw4Cu
bioclinica (2 days ago)
Vaccine clinical trials: Boost senior participation following simple advice from Dr. Craig Curtis… https://t.co/rYg9u25vMf
bioclinica (5 days ago)

Latest Blogs: